Laser Treatment for Retinopathy of Prematurity: A Decade since ETROP

Emami, Seema; Isaac, Maram; Mireskandari, Kamiar; Tehrani, Nasrin

doi:10.1016/j.ophtha.2018.12.012

Cited by 8 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second stage of ROP is characterized by retinal neovascularization and starts around 32 weeks of PMA 2 . Main treatment options for ROP include laser‐photocoagulation and intravitreal anti‐VEGF injections 3‐6 …”

Section: Introductionmentioning

confidence: 99%

Natural history and outcomes of stage 3 retinopathy of prematurity persisting beyond 40 weeks of post‐menstrual age: Dilemma for treatment and follow up

Koucheki

Isaac

Tehrani

et al. 2020

Clinical Exper Ophthalmology

Self Cite

View full text Add to dashboard Cite

Importance: To evaluate the natural history and outcomes of infants with stage-3 retinopathy of prematurity (ROP) persisting beyond 40-weeks of postmenstrual age (PMA). Background: There are no specific screening guidelines for stage-3 ROP persisting beyond 40 weeks of PMA. Persistent stage-3 disease in zone II without plus disease or in zone III with or without plus disease poses a dilemma for treatment. Design: Retrospective chart review. Participant: Neonates with stage-3 ROP persisting beyond 40-weeks of PMA. Methods: Demographic data and ROP parameters were collected. Univariate/ multivariate analyses were utilized to assess risk factors associated with requiring treatment. Main Outcome Measures: Evaluating the structural outcomes for infants with stage-3 ROP persisting beyond 40 weeks of PMA. Results: Out of 2356 screened infants, 115 infants (4.9%, 172 eyes) met inclusion criteria. In 95 infants (139 eyes, 80.8%), ROP resolved spontaneously. Twenty-one infants (33 eyes, 19.2%) were treated with laser-photocoagulation; 16 eyes had reached type 1 ROP and 17 eyes had non-type 1 ROP. No eye had unfavourable structural outcome. On multiple regression, non-type 1 ROP with ≥2 continuous clock hours of persistent stage-3 temporally crossing the horizontal midline was a significant risk factor associated with receiving treatment (OR = 27.29, 95% CI = [1.61, 462.92], P = .0221). Conclusion and Relevance: The majority of stage-3 ROP persisting beyond 40-weeks of PMA resolve spontaneously. In eyes that do not reach type 1 ROP, ≥2 continuous clock hours of persistent stage-3 crossing the temporal horizontal midline and history of pre-plus were considered important risk factors for macular drag and treatment can be considered.

show abstract

Section: Introductionmentioning

confidence: 99%

Natural history and outcomes of stage 3 retinopathy of prematurity persisting beyond 40 weeks of post‐menstrual age: Dilemma for treatment and follow up

Koucheki

Isaac

Tehrani

et al. 2020

Clinical Exper Ophthalmology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Prognosis of retinopathy of prematurity after ETROP study and in the anti-VEGF era. 6%, 14.3% 26.4%, and 15.7% achieved VA of 20/40 or better, worse than 20/40 and better than or equal to 20/60, worse than 20/60 and better than 20/200, and worse or equal to 20/200 at 6 years of age 103)• 59.2%, 31.7%, and 9.1% achieved normal, below normal, and unfavorable VA at 3 years of age117) …”

mentioning

confidence: 96%

Retinopathy of prematurity: a review of epidemiology and current treatment strategies

2022

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is among the most common causes of childhood blindness. Three phases of ROP epidemics have been observed worldwide since ROP was first described in the 1940s.Despite advances in neonatal care, the occurrence of ROP and associated visual impairment has been increasing somewhere on Earth and remains difficult to control. Conventional treatment options for preventing ROP progression include retinal ablation using cryotherapy or laser therapy. With the emergence of anti-vascular endothelial growth factor (anti-VEGF) treatment for ocular diseases, the efficacy and safety of anti-VEGF therapy for ROP have recently been actively discussed. In the advanced stage of ROP with retinal detachment, surgical treatment including scleral buckling or vitrectomy is needed to maintain or induce retinal attachment. At this stage, the visual outcome is usually poor despite successful anatomical retinal attachment. Therefore, preventing ROP progression by timely screening examinations and treatment remains the most important part of ROP management.

show abstract

“…The intervention was done in the presence of any ROP with plus disease in zone 1, stage 2 with plus disease, and stage 3 ROP in zone I or II. Laser treatment was done per standards (Emami et al, 2019). The ROP patients not requiring any treatment were called after every 2 weeks till the gestational age of 40 weeks or the complete vascularization of the retina, whichever occurred first.…”

Section: Methodsmentioning

confidence: 99%

Relation of Retinopathy of Prematurity With Change in Birth Weight During the Postnatal Period in Premature Infants in a Tertiary Care Hospital in Lahore

Chauhan

SAIGOL

Rauf

et al. 2023

Biol Clin Sci Res J

View full text Add to dashboard Cite

This study assessed the relationship between Retinopathy of Prematurity (ROP) and post-natal weight gain in premature infants admitted to the Neonatal Intensive Care Unit (NICU). The observational study was conducted in the Department of Ophthalmology in collaboration with the Department of Pediatrics, the neonatal intensive care unit (NICU) at Sir Ganga Ram hospital in Lahore from September 2020 to August 2022. Data including gender, Birth Weight (BW), Gestational Age (GA), and post-natal complications(hypotension, packed red cell transfusion, intraventricular hemorrhage, necrotizing enterocolitis, and respiratory distress syndrome) of all the premature infants with gestational age less than 35 weeks, admitted in NICU was collected. All these premature infants underwent eye examination for the presence or absence of ROP, and weight was measured. In the second, fourth, and sixth weeks, their relative weight gain(RWG) was calculated. Infants with ROP had lower BW (P <0.001) and GA (P<0.001). More infants with severe ROP had body weight <1000g and post-natal complications than those without ROP. Moreover, RWG at the 2nd and 4th weeks was lower in infants with ROP than with no ROP infants. Based on the result, it can be concluded that the ROP was associated with low postnatal weight gain, birth weight, and gestational age.

show abstract

Laser Treatment for Retinopathy of Prematurity: A Decade since ETROP

Cited by 8 publications

References 4 publications

Natural history and outcomes of stage 3 retinopathy of prematurity persisting beyond 40 weeks of post‐menstrual age: Dilemma for treatment and follow up

Natural history and outcomes of stage 3 retinopathy of prematurity persisting beyond 40 weeks of post‐menstrual age: Dilemma for treatment and follow up

Retinopathy of prematurity: a review of epidemiology and current treatment strategies

Relation of Retinopathy of Prematurity With Change in Birth Weight During the Postnatal Period in Premature Infants in a Tertiary Care Hospital in Lahore

Contact Info

Product

Resources

About